Oxford Biomedica plc

LSE:OXB Stock Report

Market Cap: UK£430.9m

Oxford Biomedica Valuation

Is OXB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OXB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OXB (£4.1) is trading below our estimate of fair value (£18.07)

Significantly Below Fair Value: OXB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXB?

Key metric: As OXB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OXB. This is calculated by dividing OXB's market cap by their current revenue.
What is OXB's PS Ratio?
PS Ratio4.4x
SalesUK£97.28m
Market CapUK£430.92m

Price to Sales Ratio vs Peers

How does OXB's PS Ratio compare to its peers?

The above table shows the PS ratio for OXB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
BVXP Bioventix
14.4xn/aUK£195.7m
GNS Genus
1.7x3.5%UK£1.1b
AVCT Avacta Group
7.3x14.3%UK£165.4m
TRX Tissue Regenix Group
1.7x15.1%UK£43.5m
OXB Oxford Biomedica
4.4x21.0%UK£432.0m

Price-To-Sales vs Peers: OXB is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (6.3x).

Price to Sales Ratio vs Industry

How does OXB's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.8x20.2%
OXB Oxford Biomedica
 4.4x21.0%US$544.58m
GNS Genus
1.7x3.5%US$1.40b
TRX Tissue Regenix Group
1.7x15.1%US$54.78m
OXB 4.4xIndustry Avg. 7.8xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.8x37.2%
OXB Oxford Biomedica
 4.4x93.2%US$544.58m
No more companies

Price-To-Sales vs Industry: OXB is good value based on its Price-To-Sales Ratio (4.4x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is OXB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: OXB is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OXB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£4.10
UK£5.13
+25.0%
22.2%UK£7.40UK£3.80n/a8
Nov ’25UK£4.05
UK£5.17
+27.7%
23.3%UK£7.40UK£3.80n/a7
Oct ’25UK£3.82
UK£4.96
+30.1%
28.4%UK£7.40UK£3.05n/a7
Sep ’25UK£3.35
UK£4.74
+41.4%
34.7%UK£7.40UK£2.50n/a7
Aug ’25UK£3.72
UK£4.49
+20.7%
36.8%UK£7.40UK£2.50n/a8
Jul ’25UK£2.97
UK£4.49
+51.1%
36.8%UK£7.40UK£2.50n/a8
Jun ’25UK£3.31
UK£4.49
+35.6%
36.8%UK£7.40UK£2.50n/a8
May ’25UK£2.87
UK£4.18
+45.6%
45.6%UK£7.40UK£1.80n/a8
Apr ’25UK£2.01
UK£4.15
+106.7%
46.2%UK£7.40UK£1.80n/a8
Mar ’25UK£1.71
UK£4.24
+147.7%
41.7%UK£7.20UK£2.10n/a8
Feb ’25UK£1.78
UK£4.24
+137.4%
41.7%UK£7.20UK£2.10n/a8
Jan ’25UK£2.20
UK£4.24
+92.5%
41.7%UK£7.20UK£2.10n/a8
Dec ’24UK£1.68
UK£4.33
+157.5%
40.0%UK£7.20UK£2.65n/a7
Nov ’24UK£2.05
UK£7.14
+248.9%
93.4%UK£24.00UK£2.65UK£4.058
Oct ’24UK£3.06
UK£7.50
+145.4%
89.9%UK£24.00UK£2.65UK£3.828
Sep ’24UK£3.24
UK£9.22
+184.6%
62.9%UK£24.00UK£3.65UK£3.359
Aug ’24UK£4.50
UK£9.30
+106.7%
61.6%UK£24.00UK£3.65UK£3.729
Jul ’24UK£4.20
UK£9.29
+121.2%
61.6%UK£24.00UK£3.65UK£2.979
Jun ’24UK£4.57
UK£10.89
+138.4%
51.9%UK£24.00UK£5.25UK£3.317
May ’24UK£4.34
UK£11.48
+164.4%
52.2%UK£24.00UK£5.25UK£2.876
Apr ’24UK£4.35
UK£10.65
+145.1%
57.5%UK£24.00UK£3.60UK£2.017
Mar ’24UK£5.60
UK£10.65
+90.2%
57.5%UK£24.00UK£3.60UK£1.717
Feb ’24UK£4.23
UK£10.65
+151.8%
57.5%UK£24.00UK£3.60UK£1.787
Jan ’24UK£4.43
UK£10.65
+140.7%
57.5%UK£24.00UK£3.60UK£2.207
Dec ’23UK£4.06
UK£10.65
+162.3%
57.5%UK£24.00UK£3.60UK£1.687
Nov ’23UK£3.36
UK£13.44
+299.9%
45.8%UK£24.00UK£5.25UK£2.056

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.00

7D

-8.8%

1Y

-6.0%

hVIVO

UK£178.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.28

7D

7.4%

1Y

-14.7%